‍

In vitro fertilization (IVF) has revolutionized the field of reproductive medicine, offering hope to couples struggling with infertility. However, the success of IVF depends on various factors, including the chromosomal health of the embryos. Preimplantation Genetic Testing for Aneuploidy (PGTA) is a powerful tool that can help improve IVF outcomes by identifying chromosomally normal embryos for transfer. In this blog post, we'll explore the benefits, risks, and considerations associated with PGTA.

Understanding the Embryo Transfer Process

During an IVF cycle with PGTA, blastocysts are typically biopsied and frozen on day 5, 6, or rarely, day 7. Once the genetic testing confirms the presence of chromosomally normal embryos, a frozen embryo transfer (FET) cycle is performed. The decision to pursue a fresh or frozen embryo transfer is an important one, and we've discussed the factors to consider in our previous post Should I Transfer a Fresh or Frozen Embryo?

‍Age and Chromosomal Normality

The percentage of chromosomally normal embryos can vary widely, from 0 to 100%, in any given cycle. As a woman ages, the likelihood of having chromosomally normal embryos decreases. On average, 50-60% of blastocysts from women under 35 are chromosomally normal, while this rate drops to 15-25% for women over 40. It's crucial for patients to understand that, regardless of age, there may be cycles where no embryos are available for biopsy or found to be chromosomally normal, resulting in no embryos for transfer.

‍Benefits of PGTA

The primary benefit of PGTA is the ability to avoid transferring chromosomally abnormal embryos. Additionally, PGTA significantly reduces the risk of an ongoing pregnancy having a chromosomal problem, although it does not eliminate the risk entirely due to the small chance of a false negative result. 

‍Risks and Disadvantages

PGTA does come with some potential drawbacks. The process incurs additional costs and may slightly increase the risk of damaging an embryo during the biopsy or freeze-thaw process. Moreover, PGTA results in a delay in the embryo transfer until the genetic testing results are known. Another consideration is the small chance of a false positive result, where a normal embryo is misdiagnosed as abnormal and not transferred.

‍Single Embryo Transfer and PGTA

When PGTA is utilized, it is generally recommended to transfer a single embryo. This approach maximizes the chances of a successful pregnancy while minimizing the risks associated with multiple pregnancies. Without PGTA, it is more common to transfer multiple embryos to compensate for the possibility of chromosomally abnormal embryos, which may not implant or result in a miscarriage.

PGTA is a valuable tool in the IVF process, offering the potential to improve success rates and minimize the heartbreak of miscarriage. However, it is essential for patients to weigh the benefits, risks, and alternatives before deciding to pursue PGTA. While no technology is perfect, advancements in PGTA have made it an increasingly effective means of optimizing IVF outcomes. For a deeper dive into the PGTA process, check out our article, How is Embryo Screening Performed?

The content on this blog is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions or implementing any medical information shared here.